The research and development of a new drug is a lengthy and costly process, which requires considerable investment by the pharmaceutical industries, with a very low success rate and a constant need for innovative approaches. The so-called “reverse approach” (or target-based drug discovery) is based on the screening of small molecule libraries, to identify "hit compounds" capable of interacting and modulating the biological activity of the target of interest. In recent years, protein-protein interactions (PPI) have emerged as promising new targets, especially considering their key role in most cellular processes, under both physiological and pathological conditions.
The aim of this project is the development of an in vivo high-throughput platform based on the BRET (Bioluminescence Resonance Energy Transfer) technology as a tool to monitor PPI and to screen compound libraries for the identification of new potential PPI inhibitors.
Corbel, Caroline, Sartini, Sara, Levati, Elisabetta, Colas, Pierre, Maillet, Laurent, Couturier, Cyril, Montanini, Barbara, Bach, Stéphane (2017)
Screening for Protein-Protein Interaction Inhibitors Using a Bioluminescence Resonance Energy Transfer (BRET)-Based Assay in Yeast.
Sartini, S , Levati, E , Maccesi, M , Guerra, M , Spadoni, G , Bach, S , Benincasa, M , Scocchi, M , Ottonello, S , Rivara, S , Montanini, B (2019)
New Antimicrobials Targeting Bacterial RNA Polymerase Holoenzyme Assembly Identified with an in Vivo BRET-Based Discovery Platform.